Compare EU & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | IRWD |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.5M | 520.6M |
| IPO Year | N/A | 2010 |
| Metric | EU | IRWD |
|---|---|---|
| Price | $2.64 | $4.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $5.34 |
| AVG Volume (30 Days) | ★ 2.9M | 2.3M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | $44,142,000.00 | ★ $338,987,000.00 |
| Revenue This Year | $17.41 | N/A |
| Revenue Next Year | $95.45 | $4.01 |
| P/E Ratio | ★ N/A | $19.03 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $0.53 |
| 52 Week High | $4.19 | $4.78 |
| Indicator | EU | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 78.52 |
| Support Level | $2.35 | $3.11 |
| Resistance Level | $2.54 | $3.39 |
| Average True Range (ATR) | 0.18 | 0.29 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 64.60 | 55.37 |
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.